|
Mar 02, 2023
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Feb 24, 2023
|
BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)
|
|
|
Feb 22, 2023
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
Feb 21, 2023
|
BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
|
|
|
Feb 07, 2023
|
BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
|
|
|
Feb 06, 2023
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Feb 03, 2023
|
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
|
|
|
Jan 26, 2023
|
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema
|
|
|
Jan 23, 2023
|
BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe
|
|
|
Jan 09, 2023
|
BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance
|
|
